Organization (Academic)
Boston University
ClinicalTrials.gov lists Boston University as lead sponsor of 269 trials, counting the companies grouped under it. Boston University itself has 22 active development programs and 59 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 11 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 12 in 2026 and about 20 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 7 trials are registered to start in 2027 or later.
Logo Boston University, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Boston University and 1 company grouped under it: 269 lead-sponsored trials (269 its own, 0 in the grouped companies) and 3 legal-entity registrations (1 its own, 2 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Clinical and Translational Science Institute | 0 | 2 |
Disease areas (278)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Substance-Related Disorders | 46 |
| Anxiety Disorders | 39 |
| Stress Disorders, Post-Traumatic | 34 |
| Diabetes Mellitus | 33 |
| HIV Infections | 29 |
Showing 5 of 278 disease areas.
Trials by start year as sponsor or collaborator (31)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 7 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 11 |
| 2025 | 28 |
| 2024 | 27 |
| 2023 | 28 |
| 2022 | 32 |
| 2021 | 28 |
| 2020 | 30 |
| 2019 | 29 |
| 2018 | 21 |
| 2017 | 26 |
Showing 10 of 31 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 22 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 200 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (22)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Combination cream of 5-fluorouracil and calcipotriene | Bowen's Disease | Phase 2/3 | 1 |
| 5 Fluorouracil (5 FU) Cream | Squamous Intraepithelial Lesions | Phase 2/3 | 1 |
| 5 Fluorouracil (5 FU) Cream | Bowen's Disease | Phase 2/3 | 1 |
| Combination cream of 5-fluorouracil and calcipotriene | Squamous Intraepithelial Lesions | Phase 2/3 | 1 |
| Levofloxacin | Tuberculosis | Phase 2 | 2 |
Showing 5 of 22 active programs.
Approved assets (59)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Acetominophen | 1 |
| Physician preference strategy | 1 |
| Dapagliflozin | 1 |
| Crisaborole 2% | 1 |
| Beta-blocker strategy | 1 |
Showing 5 of 59 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 26% hit target (n=103) | 29% on time (n=87) |
Journals published in (585)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| PloS one | 33 |
| The New England journal of medicine | 33 |
| Journal of acquired immune deficiency syndromes (1999) | 25 |
| AIDS and behavior | 23 |
| JAMA | 21 |
Showing 5 of 585 journals.
Financing and grant events (915)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-04-28 | NIH grant | 438,770 | Reporter |
| 2025-09-30 | NIH grant | 8,894,939 | Reporter |
| 2025-09-30 | NIH grant | 10,000 | Reporter |
| 2025-09-22 | NIH grant | 808,919 | Reporter |
| 2025-09-22 | NIH grant | 194,110 | Reporter |
Showing 5 of 915 events.
Organization relationships (85)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Tufts University | Co sponsors trial with | 5 |
| Rutgers, The State University of New Jersey | Co sponsors trial with | 4 |
| Aditi Bunker | Co sponsors trial with | 4 |
| University of Witwatersrand, South Africa | Co sponsors trial with | 3 |
| Resene | Co sponsors trial with | 3 |
Showing 5 of 85 relationships.
Latest dated events (1,574)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2028-05-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 1,574 events.
Biomarker capability evidence (373)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCB1 | Trial collaborator | Named in trial inclusion criteria |
| ACAT1 | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 373 evidence rows.
Biomarkers this organization publishes on (834)
Shown in this order: most publications first.
Showing 5 of 834 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.